✦ LIBER ✦

A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours

✍ Scribed by Rasschaert, M; Schrijvers, D; Van den Brande, J; Dyck, J; Bosmans, J; Merkle, K; Vermorken, J B

Book ID: 109999158
Publisher: Nature Publishing Group
Year: 2007
Tongue: English
Weight: 120 KB
Volume: 96
Category: Article
ISSN: 0007-0920
DOI: 10.1038/sj.bjc.6603776

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I study of cisplatin, irinotecan,

Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours

✍ Chen, X; Oza, A M; Kusenda, Z; Yi, Q-L; Kochman, D; Moore, M J; Davis, A J; Siu, 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 127 KB

A phase I study with MAG-camptothecin in

A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours

✍ Wachters, F M; Groen, H J M; Maring, J G; Gietema, J A; Porro, M; Dumez, H; de V 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 117 KB

Repeated administration of short infusio

Repeated administration of short infusions of bendamustine: a phase I study in patients with advanced progressive solid tumours

✍ P. Schöffski; T. Hagedorn; V. Grünwald; H. Paul; K. Merkle; R. Kowalski; A. Gans 📂 Article 📅 2000 🏛 Springer-Verlag 🌐 English ⚖ 111 KB

A Phase I study of raltitrexed and pacli

A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors

✍ Everett E. Vokes; Boon C. Goh; Donna Bertucci; Nicholas J. Vogelzang; Sridhar Ma 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB 👁 2 views

## BACKGROUND. Raltitrexed is a novel thymidylate synthase inhibitor with single agent activity in colorectal, nonsmall cell lung, and breast carcinomas. The recommended Phase II dose of raltitrexed administered as a single agent is 3 mg/m 2 every 3 weeks. Paclitaxel also has a broad spectrum of a

A phase 1 study of OSI-211 given as an i

A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers

✍ K. Gelmon; H. Hirte; B. Fisher; W. Walsh; M. Ptaszynski; M. Hamilton; N. Onetto; 📂 Article 📅 2004 🏛 Springer US 🌐 English ⚖ 283 KB

A phase I study of recombinant interfero

A phase I study of recombinant interferon gamma administered by s.c. injection three times per week in patients with solid tumours

✍ John Wagstaff; David Smith; Philipp Nelmes; Peter Loynds; Derek Crowther 📂 Article 📅 1987 🏛 Springer-Verlag 🌐 English ⚖ 479 KB

Human recombinant DNA interferon gamma (IFN-G), with a specific activity of 2 x 10 6 I U / m g protein, was administered s.c. 3 days per week for 2 months to patients with solid tumors. The maximum tolerated dose (MTD) was 10 × 10 6 I U / m 2 (5.0 mg/m 2) per injection, and six patients were treated